1
|
Guzman-Esquivel J, Murillo-Zamora E, Ortiz-Mesina M, Galvan-Salazar HR, De-Leon-Zaragoza L, Casarez-Price JC, Delgado-Enciso J, Delgado-Enciso I. Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019. Int Urol Nephrol 2023; 55:2155-2160. [PMID: 37273013 PMCID: PMC10240458 DOI: 10.1007/s11255-023-03653-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 05/27/2023] [Indexed: 06/06/2023]
Abstract
PURPOSE Prostate cancer (PC) is the second leading cause of cancer and the fifth cause of cancer-related death. This manuscript aims to determine the incidence, mortality, and Disability Adjusted Life Years (DALYs) trends of PC in the last 30 years in Latin America and Mexico. METHODS We performed a cross-sectional analysis of a publicly available data set. Data regarding the burden of prostate cancer in 20 Latin-American countries, and the 32 states of Mexico, were retrieved from the Global Burden of Disease Study 2019. Collected information included incidence and mortality rates (per 100,000), as well as the DALYs as absolute numbers and rates (per 100,000) and the annual rates of change in rates from 1990 to 2019. RESULTS In Latin America in males aged 55 years or older, the mean incidence rate was 344 cases per 100,000. The number of deaths attributable to prostate cancer observed was 67,110 and the mean mortality rate was 210 per 100,000. The overall burden of disease was 1,120,709 DALYs and the contribution of years of life lost (YLL) was 91.7% ([Formula: see text] = 1,027,946). Mexico presented an incidence rate (279.6) and mortality (99.1) rate (per /100 thousand). In Mexico, 13 states had a DALYs' rate above the national mean (883 per 100,000) and the highest burden (1360 DALYs/100,000) were documented in the state of Guerrero (Southwestern Mexico). CONCLUSION Only two Latin-American countries (Brazil and Colombia) and eight states of Mexico showed a decreased trend about the rate of change of DALYs in the last 30 years.
Collapse
Affiliation(s)
- Jose Guzman-Esquivel
- Clinical Epidemiology Research Unit, Mexican Social Security Institute, Av. Lapislazuli No. 250, El Haya, 28984, Villa de Álvarez, Colima, Mexico
| | - Efren Murillo-Zamora
- Clinical Epidemiology Research Unit, Mexican Social Security Institute, Av. Lapislazuli No. 250, El Haya, 28984, Villa de Álvarez, Colima, Mexico
| | - Monica Ortiz-Mesina
- Headquarters of Medical Services, Mexican Social Security Institute, Doroteo López 442, Col. Magisterial, Colima, Mexico
| | - Hector R Galvan-Salazar
- Clinical Laboratory, Mexican Social Security Institute. HGZ1, Av. Lapislazuli No. 250, El Haya, 28984, Villa de Álvarez, Colima, Mexico
| | - Luis De-Leon-Zaragoza
- Department of Research, Cancerology State Institute, Colima State Health Services, Liceo de Varones 401, La Esperanza, 28085, Colima, Colima, Mexico
| | - Juan C Casarez-Price
- Department of Research, Cancerology State Institute, Colima State Health Services, Liceo de Varones 401, La Esperanza, 28085, Colima, Colima, Mexico
| | - Josuel Delgado-Enciso
- Foundation for Ethics Education and Cancer Research of the IEC of Colima AC, Av. Liceo de Varones 401 Colonia la Esperanza, 28085, Colima, Mexico
| | - Ivan Delgado-Enciso
- Department of Research, Cancerology State Institute, Colima State Health Services, Liceo de Varones 401, La Esperanza, 28085, Colima, Colima, Mexico.
- Molecular Biology Laboratory, School of Medicine, University of Colima, Av. Universidad 333, colonia la Esperanza, 28040, Colima, Mexico.
| |
Collapse
|
2
|
Guzman-Esquivel J, Galvan-Salazar HR, Guzman-Solorzano HP, Cuevas-Velazquez AC, Guzman-Solorzano JA, Mokay-Ramirez KA, Paz-Michel BA, Murillo-Zamora E, Delgado-Enciso J, Melnikov V, Delgado-Enciso OG, Rodriguez-Sanchez IP, Martinez-Fierro ML, Rojas-Larios F, Walle-Guillen M, Cardenas-Aguilar CB, Beas-Guzman O, Chaviano-Conesa D, Garcia-Garcia HS, Delgado-Enciso I. Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial. Int J Mol Med 2022; 49:29. [PMID: 35029292 DOI: 10.3892/ijmm.2022.5084] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 12/23/2021] [Indexed: 11/06/2022] Open
Abstract
Mefenamic acid is a non‑steroidal anti‑inflammatory drug exhibiting a wide range of anti‑inflammatory, antipyretic, analgesic and probable antiviral activities. The present study evaluated the efficacy of treatment with mefenamic acid combined with standard medical care vs. standard medical care plus a placebo in ambulatory patients with coronavirus disease 2019 (COVID‑19; nasal/oropharyngeal swabs reverse transcription‑PCR test results positive for severe acute respiratory syndrome coronavirus 2). The present study is a phase II prospective, two‑arm, parallel‑group, randomized, double‑blind placebo‑controlled clinical trial which analyzed 36 patients. Two aspects were evaluated during the 14‑day follow‑up period: i) The time for reaching a patient acceptable symptom state (PASS), and ii) the last day of each COVID‑19 symptom presentation. Adverse effects were evaluated. The clinical severity for all the patients in the study was mild (88.9%) and moderate (11.1%). The control (placebo) group achieved PASS on day 8.0±1.3, compared with day 4.4±0.8 in the mefenamic acid group (P=0.020, Kaplan‑Meier analyses using log‑rank tests). Patients that received mefenamic acid plus standard medical care had a ~16‑fold higher probability of achieving PASS on day 8 (adjusted RR, 15.57; 95% CI, 1.22‑198.71; P=0.035), compared with the placebo plus standard medical care group. All symptoms lasted for fewer days in the mefenamic acid group, compared with the placebo group; however, only the symptoms of headache (P=0.008), retro‑orbital eye pain (P=0.049), and sore throat (P=0.029) exhibited statistically significant differences. The experimental treatment produced no severe adverse effects. On the whole, the present study demonstrates that the administration of mefenamic acid markedly reduced the symptomatology and time to reach PASS in ambulatory patients with COVID‑19. Due to its probable antiviral effects and potent anti‑inflammatory mechanisms, mefenamic acid may prove to be useful in the treatment of COVID‑19, in combination with other drugs, including the new antivirals (remdesivir, molnupiravir, or favipiravir). However, future studies are also required to confirm these findings.
Collapse
Affiliation(s)
- Jose Guzman-Esquivel
- Department of Research, General Hospital of Zone No. 1 IMSS, Villa de Alvarez, Colima 28984, Mexico
| | - Hector R Galvan-Salazar
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | | | | | - Jose A Guzman-Solorzano
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Karen A Mokay-Ramirez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Brenda A Paz-Michel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Efren Murillo-Zamora
- Department of Research, General Hospital of Zone No. 1 IMSS, Villa de Alvarez, Colima 28984, Mexico
| | - Josuel Delgado-Enciso
- Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, Mexico
| | - Valery Melnikov
- Department of Research, General Hospital of Zone No. 1 IMSS, Villa de Alvarez, Colima 28984, Mexico
| | - Osiris G Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Iram P Rodriguez-Sanchez
- Laboratory of Molecular and Structural Physiology, School of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo León 66455, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico
| | - Fabian Rojas-Larios
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Mireya Walle-Guillen
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | | | - Oscar Beas-Guzman
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Daniel Chaviano-Conesa
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Hossana S Garcia-Garcia
- Department of Research, General Hospital of Zone No. 1 IMSS, Villa de Alvarez, Colima 28984, Mexico
| | - Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| |
Collapse
|
3
|
Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, Melnikov V, Walle-Guillen M, Galvan-Salazar HR, Delgado-Enciso OG, Cabrera-Licona A, Danielewicz-Mata EJ, Mandujano-Diaz PJ, Guzman-Esquivel J, Montes-Galindo DA, Perez-Martinez H, Jimenez-Villegaz JM, Hernandez-Rangel AE, Montes-Diaz P, Rodriguez-Sanchez IP, Martinez-Fierro ML, Garza-Veloz I, Tiburcio-Jimenez D, Zaizar-Fregoso SA, Gonzalez-Alcaraz F, Gutierrez-Gutierrez L, Diaz-Lopez L, Ramirez-Flores M, Guzman-Solorzano HP, Gaytan-Sandoval G, Martinez-Perez CR, Espinoza-Gómez F, Rojas-Larios F, Hirsch-Meillon MJ, Baltazar-Rodriguez LM, Barrios-Navarro E, Oviedo-Rodriguez V, Mendoza-Hernandez MA, Prieto-Diaz-Chavez E, Paz-Michel BA. Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. Exp Ther Med 2021; 22:915. [PMID: 34306189 PMCID: PMC8281484 DOI: 10.3892/etm.2021.10347] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 05/11/2021] [Indexed: 12/13/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is currently the major public health problem worldwide. Neutral electrolyzed saline solution that contains reactive chlorine and oxygen species may be an effective therapeutic. In the present study, the treatment efficacy of intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care vs. usual medical care alone was evaluated in ambulatory patients with COVID-19. A prospective, 2-arm, parallel-group, randomized, open-label, multi-center, phase I-II clinical trial including 214 patients was performed. The following two outcomes were evaluated during the 20-day follow-up: i) The number of patients with disease progression; and ii) the patient acceptable symptom state. Serial severe acute respiratory syndrome coronavirus 2 naso/oro-pharyngeal detection by reverse transcription-quantitative (RT-q) PCR was performed in certain patients of the experimental group. Biochemical and hematologic parameters, as well as adverse effects, were also evaluated in the experimental group. The experimental treatment decreased the risk of hospitalization by 89% [adjusted relative risk (RR)=0.11, 95% confidence interval (CI): 0.03-0.37, P<0.001] and the risk of death by 96% (adjusted RR=0.04, 95% CI: 0.01-0.42, P=0.007) and also resulted in an 18-fold higher probability of achieving an acceptable symptom state on day 5 (adjusted RR=18.14, 95% CI: 7.29-45.09, P<0.001), compared with usual medical care alone. Overall, neutral electrolyzed saline solution was better than usual medical care alone. Of the patients analyzed, >50% were negative for the virus as detected by RT-qPCR in naso/oro-pharyngeal samples on day 4, with only a small number of positive patients on day 6. Clinical improvement correlated with a decrease in C-reactive protein, aberrant monocytes and increased lymphocytes and platelets. Cortisol and testosterone levels were also evaluated and a decrease in cortisol levels and an increase in the testosterone-cortisol ratio were observed on days 2 and 4. The experimental treatment produced no serious adverse effects. In conclusion, neutral electrolyzed saline solution markedly reduced the symptomatology and risk of progression in ambulatory patients with COVID-19. The present clinical trial was registered in the Cuban public registry of clinical trials (RPCEC) database (May 5, 2020; no. TX-COVID19: RPCEC00000309).
Collapse
Affiliation(s)
- Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Juan Paz-Garcia
- Department of Internal Medicine and Surgery, Union Hospital Center, Villa de Álvarez, Colima 28970, México
| | - Carlos E Barajas-Saucedo
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Karen A Mokay-Ramírez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Carmen Meza-Robles
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Rodrigo Lopez-Flores
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Marina Delgado-Machuca
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Efren Murillo-Zamora
- Department of Research, General Hospital of Zone No. 1 and Family Medicine Unit No. 19 IMSS, Villa de Alvarez, Colima 28984, México
| | - Jose A Toscano-Velazquez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Josuel Delgado-Enciso
- Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | - Valery Melnikov
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Mireya Walle-Guillen
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Hector R Galvan-Salazar
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Osiris G Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | | | | | - Pablo J Mandujano-Diaz
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | - José Guzman-Esquivel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | - Daniel A Montes-Galindo
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Henry Perez-Martinez
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | | | | | | | - Iram P Rodriguez-Sanchez
- Laboratory of Molecular and Structural Physiology, School of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo León 66455, México
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, México
| | - Idalia Garza-Veloz
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, México
| | - Daniel Tiburcio-Jimenez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Sergio A Zaizar-Fregoso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | | | | | - Luciano Diaz-Lopez
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | - Mario Ramirez-Flores
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | | | - Gustavo Gaytan-Sandoval
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Carlos R Martinez-Perez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Francisco Espinoza-Gómez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Fabián Rojas-Larios
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Michael J Hirsch-Meillon
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Luz M Baltazar-Rodriguez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Enrique Barrios-Navarro
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Vladimir Oviedo-Rodriguez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | | | | | - Brenda A Paz-Michel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Esteripharma S.A. de C.V., Ciudad de México 03100, México
| |
Collapse
|
4
|
Melnikov V, Tiburcio-Jimenez D, Mendoza-Hernandez MA, Delgado-Enciso J, De-Leon-Zaragoza L, Guzman-Esquivel J, Rodriguez-Sanchez IP, Martinez-Fierro ML, Lara-Esqueda A, Delgado-Enciso OG, Jacinto-Cortes I, Zaizar-Fregoso SA, Paz-Michel BA, Murillo-Zamora E, Delgado-Enciso I, Galvan-Salazar HR. Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy. Am J Transl Res 2021; 13:4535-4543. [PMID: 34150033 PMCID: PMC8205720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 03/20/2021] [Indexed: 06/12/2023]
Abstract
Inflammation is an essential component of prostate cancer (PCa), and mefenamic acid has been reported to decrease its biochemical progression. The current standard therapy for PCa is androgen deprivation therapy (ADT), which has side effects such as cognitive dysfunction, risk of Alzheimer's disease, and dementia. Published results of in vitro tests and animal models studies have shown that mefenamic acid could be used as a neuroprotector. Objective: Examine the therapeutic potential of mefenamic acid in cognitive impairment used in a controlled clinical trial. Clinical trial phase II was conducted on patients undergoing ADT for PCa. Two groups of 14 patients were included. One was treated with a placebo, while the other received mefenamic acid 500 mg PO every 12hrs for six months. The outcome was evaluated through the Mini-Mental State Examination (MMSE) score at six months. At the beginning of the study, both groups had similar MMSE scores (mefenamic acid vs. placebo: 26.0±2.5 vs. 27.0±2.6, P=0.282). The mefenamic acid group improved its MMSE score after six months compared with the placebo group (27.7±1.8 vs. 25.5±4.2, P=0.037). Treatment with mefenamic acid significantly increases the probability of maintained or raised cognitive function compared to placebo (92% vs. 42.9%, RR=2.2, 95% CI: 1.16-4.03, NNT=2.0, 95% CI: 1.26-4.81, P=0.014). Furthermore, 42.9% of the placebo group patients had relevant cognitive decline (a 2-point decrease in the MMSE score), while in patients treated with mefenamic acid, cognitive impairment was not present. This study is the first conducted on humans that suggests that mefenamic acid protects against cognitive decline.
Collapse
Affiliation(s)
- Valery Melnikov
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
| | - Daniel Tiburcio-Jimenez
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
| | | | - Josuel Delgado-Enciso
- Department of Research, Foundation for Cancer Ethics, Education and Research of The Cancerology State InstituteColima, Mexico
| | - Luis De-Leon-Zaragoza
- Department of Research, Cancerology State Institute, Colima State Health ServicesColima, Mexico
| | - Jose Guzman-Esquivel
- Department of Research, General Hospital of Zone No. 1 IMSSVilla de Alvarez, Colima, Mexico
| | - Iram P Rodriguez-Sanchez
- Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo LeonMonterrey, Nuevo Leon, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of ZacatecasZacatecas, Mexico
| | - Agustin Lara-Esqueda
- Department of Research, Cancerology State Institute, Colima State Health ServicesColima, Mexico
| | - Osiris G Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
- Department of Research, Foundation for Cancer Ethics, Education and Research of The Cancerology State InstituteColima, Mexico
| | - Ivan Jacinto-Cortes
- Department of Research, Cancerology State Institute, Colima State Health ServicesColima, Mexico
| | - Sergio A Zaizar-Fregoso
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
| | - Brenda A Paz-Michel
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
| | | | - Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of ColimaColima 28040, Mexico
- Department of Research, Cancerology State Institute, Colima State Health ServicesColima, Mexico
| | - Hector R Galvan-Salazar
- Department of Research, Cancerology State Institute, Colima State Health ServicesColima, Mexico
- Department of Research, General Hospital of Zone No. 1 IMSSVilla de Alvarez, Colima, Mexico
| |
Collapse
|
5
|
Lara-Esqueda A, Zaizar-Fregoso SA, Madrigal-Perez VM, Ramirez-Flores M, Montes-Galindo DA, Martinez-Fierro ML, Rodriguez-Sanchez IP, Guzman-Esquivel J, Meza-Robles C, Ceja-Espiritu G, Kuri-Morales PA, Delgado-Enciso J, Barriguete-Melendez A, Galvan-Salazar HR, Barajas-Saucedo CE, Guillermo-Espinosa E, Lara-Basulto AD, Gonzalez-Roldan JF, Delgado-Enciso I. Evaluation of Medical Care for Diabetic and Hypertensive Patients in Primary Care in Mexico: Observational Retrospective Study. J Diabetes Res 2021; 2021:7365075. [PMID: 34426789 PMCID: PMC8380161 DOI: 10.1155/2021/7365075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 07/22/2021] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION The present study evaluated the quality of medical care for patients diagnosed with diabetes mellitus (DM), hypertension (HBP), and both pathologies (DM+HBP) within a public health system in Mexico. METHODS 45,498 patients were included from 2012 to 2015. All information was taken from the electronic medical record database. Each patient record was compared against the standard to test the quality of medical care. RESULTS Glycemia with hypertension goals reached 29.6% in DM+HBP, 48.6% in DM, and 53.2% in HBP. The goals of serum lipids were reached by 3% in DM+HBP, 5% in DM, and 0.2% in HBP. Glycemia, hypertension, and LDL cholesterol reached 0.04%. 15% of patients had an undiagnosed disease. Clinical follow-up examinations reached 20% for foot examination and clinical eye examination. Specialty referrals reached 1% in angiology or cardiology. CONCLUSION Goals for glycemic and hypertension reached 50% in the overall population, while serum lipids, clinical follow-up examinations, and referral to a specialist were deficient. Patients who had both diseases had more consultations, better control for hypertension and lipids, but inferior glycemic control. Overall, quality care for DM and/or HBP has not been met according to the standards.
Collapse
Affiliation(s)
- Agustin Lara-Esqueda
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Sergio A. Zaizar-Fregoso
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Violeta M. Madrigal-Perez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Mario Ramirez-Flores
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Daniel A. Montes-Galindo
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Margarita L. Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University, Zacatecas 98160, Mexico
| | - Iram P. Rodriguez-Sanchez
- Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico
| | - José Guzman-Esquivel
- Department of Research, Mexican Social Security Institute, Villa de Alvarez, Colima 28983, Mexico
| | - Carmen Meza-Robles
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Gabriel Ceja-Espiritu
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Pablo A. Kuri-Morales
- School of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, 04510, Mexico
| | - Josuel Delgado-Enciso
- Fundación para la Etica, Education e Investigación del Cáncer del Instituto Estatal de Cancerologia de Colima, Colima 28085, Mexico
| | | | - Hector R. Galvan-Salazar
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | | | | | - Agustin D. Lara-Basulto
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Jesus F. Gonzalez-Roldan
- Subsecretaria de Prevención y Promoción de la Salud, Secretaria de Salud de Mexico, Ciudad de Mexico, 06600, Mexico
| | - Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| |
Collapse
|
6
|
Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, Melnikov V, Walle-Guillen M, Galvan-Salazar HR, Delgado-Enciso OG, Cabrera-Licona A, Guzman-Esqu J, Montes-Galindo DA, Hernandez-Rangel AE, Montes-Diaz P, Rodriguez-Sanchez IP, Martinez-Fierro ML, Garza-Veloz I, Tiburcio-Jimenez D, Zaizar-Fregoso SA, Ramirez-Flores M, Gaytan-Sandoval G, Martinez-Perez CR, Espinoza-Gómez F, Rojas-Larios F, Hirsch-Meillon MJ, Barrios-Navarro E, Oviedo-Rodriguez V, Rodriguez LMB, Paz-Michel BA. Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. Res Sq 2020. [PMID: 32935090 PMCID: PMC7491578 DOI: 10.21203/rs.3.rs-68403/v1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Background: Coronavirus disease (COVID-19) is currently the main public health problem worldwide. The administration of neutral electrolyzed saline, a solution that contains reactive species of chlorine and oxygen (ROS), may be an effective therapeutic alternative due to its immunomodulating characteristics, in systemic inflammation control, as well as in immune response improvement, promoting control of the viral infection. The present study evaluated the efficacy of treatment with intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19. Methods: A prospective, 2-arm, parallel group, randomized, open-label, phase I-II clinical trial included 39 patients in the control group (usual medical care alone) and 45 patients in the experimental group (usual medical care + intravenous and/or nebulized electrolyzed saline, with dose escalation). Two aspects were evaluated during the twenty-day follow-up: i) the number of patients with disease progression (hospitalization or death); and ii) the Patient Acceptable Symptom State (PASS), a single-question outcome that determines patient well-being thresholds for pain and function. Biochemical and hematologic parameters, as well as adverse effects, were evaluated in the experimental group. Results: The experimental treatment decreased the risk for hospitalization by 92% (adjusted RR=0.08, 95% CI: 0.01–0.50, P=0.007), with a 43-fold increase in the probability of achieving an acceptable symptom state on day 5 (adjusted RR= 42.96, 95% CI: 9.22–200.0, P<0.001). Intravenous + nebulized administration was better than nebulized administration alone, but nebulized administration was better than usual medical care alone. Clinical improvement correlated with a decrease in C-reactive protein, and aberrant monocytes and an increase of lymphocytes, and platelets. Cortisol and testosterone levels were also evaluated, observing a decrease in cortisol levels and an increment of testosterone-cortisol ratio, on days 2 and 4. Conclusions: The experimental treatment produced no serious adverse effects. In conclusion, intravenous and/or nebulized neutral electrolyzed saline importantly reduced the symptomatology and risk of progression (hospitalization and death), in ambulatory patients with COVID-19. Trial registration: Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000309. Registered: 05. May 2020. https://rpcec.sld.cu/en/trials/RPCEC00000309-En
Collapse
|
7
|
Delgado-Enciso I, Paz-Garcia J, Valtierra-Alvarez J, Preciado-Ramirez J, Almeida-Trinidad R, Guzman-Esquivel J, Mendoza-Hernandez MA, Garcia-Vega A, Soriano-Hernandez AD, Cortes-Bazan JL, Galvan-Salazar HR, Cabrera-Licona A, Rodriguez-Sanchez IP, Martinez-Fierro ML, Delgado-Enciso J, Paz-Michel B. A phase I-II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee. Eur J Med Res 2018; 23:52. [PMID: 30355362 PMCID: PMC6199741 DOI: 10.1186/s40001-018-0349-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 10/15/2018] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND A promising novel cell-free bioactive formulation for articular cartilage regeneration, called BIOF2, has recently been tested in pre-clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 for intra-articular application in patients with severe osteoarthritis of the knee. METHODS A prospective, randomized, 3-arm, parallel group clinical trial was conducted. It included 24 patients with severe osteoarthritis of the knee (WOMAC score 65.9 ± 17). Before they entered the study, all the patients were under osteoarthritis control through the standard treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), prescribed by their family physician. Patients were distributed into three groups of 8 patients each (intra-articular BIOF2, total joint arthroplasty, or conservative treatment with NSAIDs alone). The WOMAC score, RAPID3 score, and Rasmussen clinical score were evaluated before treatment and at months 3, 6, and 12. BIOF2 was applied at months 0, 3, and 6. Complete blood count and blood chemistry parameters were determined in the BIOF2 group before treatment, at 72 h, and at months 1, 3, 6, and 12. In addition, articular cartilage volume was evaluated (according to MRI) at the beginning of the study and at month 12. RESULTS The NSAID group showed no improvement at follow-up. Arthroplasty and BIOF2 treatments showed significant improvement in all the scoring scales starting at month 3. There were no statistically significant differences between the BIOF2 group and the arthroplasty group at month 6 (WOMAC score: 19.3 ± 18 vs 4.3 ± 5; P = 0.24) or month 12 (WOMAC score: 15.6 ± 15 vs 15.7 ± 17; P = 1.0). Arthroplasty and BIOF2 were successful at month 12 (according to a WOMAC score: ≤ 16) in 75% of the patients and the daily use of NSAIDs was reduced, compared with the group treated exclusively with NSAIDs (RR = 0.33, 95% CI 0.12-0.87, P = 0.02. This result was the same for BIOF2 vs NSAIDs and arthroplasty vs NSAIDs). BIOF2 significantly increased the articular cartilage by 22% (26.1 ± 10 vs 31.9 ± 10 cm2, P < 0.001) and produced a significant reduction in serum lipids. BIOF2 was well tolerated, causing slight-to-moderate pain only upon application. CONCLUSIONS The intra-articular application of the new bioactive cell-free formulation (BIOF2) was well tolerated and showed no significative differences with arthroplasty for the treatment of severe osteoarthritis of the knee. BIOF2 can regenerate articular cartilage and is an easily implemented alternative therapy for the treatment of osteoarthritis. Trial registration Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000250. Registered 08/15/2017-Retrospectively registered, http://rpcec.sld.cu/en/trials/RPCEC00000250-En .
Collapse
MESH Headings
- Adult
- Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
- Anti-Inflammatory Agents, Non-Steroidal/pharmacology
- Arthroplasty, Replacement, Knee
- Blood Cell Count
- Cartilage, Articular/drug effects
- Cartilage, Articular/growth & development
- Cell-Free System/chemistry
- Cell-Free System/metabolism
- Chondrocytes/drug effects
- Chondrogenesis/drug effects
- Female
- Humans
- Injections, Intra-Articular
- Male
- Mesenchymal Stem Cells/chemistry
- Mesenchymal Stem Cells/metabolism
- Middle Aged
- Osteoarthritis, Knee/blood
- Osteoarthritis, Knee/drug therapy
- Osteoarthritis, Knee/physiopathology
- Osteoarthritis, Knee/surgery
- Regeneration/drug effects
- Steroids/administration & dosage
- Steroids/pharmacology
- Treatment Outcome
Collapse
Affiliation(s)
- Ivan Delgado-Enciso
- Instituto Estatal de Cancerologia, Colima State Health Services, 28000, Colima, Mexico
- School of Medicine, University of Colima, 28030, Colima, Mexico
| | - Juan Paz-Garcia
- Centro Hospitalario Union, Villa de Álvarez, 28970, Colima, Mexico
| | | | | | | | | | | | - Alberto Garcia-Vega
- Hospital General de Zona No. 1 IMSS, Villa de Álvarez, 28983, Colima, Mexico
| | - Alejandro D Soriano-Hernandez
- Instituto Estatal de Cancerologia, Colima State Health Services, 28000, Colima, Mexico
- School of Medicine, University of Colima, 28030, Colima, Mexico
| | - Jose L Cortes-Bazan
- Instituto Estatal de Cancerologia, Colima State Health Services, 28000, Colima, Mexico
| | - Hector R Galvan-Salazar
- School of Medicine, University of Colima, 28030, Colima, Mexico
- Hospital General de Zona No. 1 IMSS, Villa de Álvarez, 28983, Colima, Mexico
| | - Ariana Cabrera-Licona
- Esteripharma México, S.A. de C.V, Patricio Sanz 1582, Colonia del Valle Centro, 03100, Ciudad de México, Mexico
| | - Iram P Rodriguez-Sanchez
- School of Biological Sciences, Universidad Autonoma de Nuevo Leon, 64460, Monterrey, Nuevo León, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Universidad Autónoma de Zacatecas, 98160, Zacatecas, Mexico
| | - Josuel Delgado-Enciso
- Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, 28085, Colima, Mexico
| | - Brenda Paz-Michel
- Esteripharma México, S.A. de C.V, Patricio Sanz 1582, Colonia del Valle Centro, 03100, Ciudad de México, Mexico.
| |
Collapse
|
8
|
Delgado-Enciso I, Paz-Garcia J, Rodriguez-Hernandez A, Madrigal-Perez VM, Cabrera-Licona A, Garcia-Rivera A, Soriano-Hernandez AD, Cortes-Bazan JL, Galvan-Salazar HR, Valtierra-Alvarez J, Guzman-Esquivel J, Rodriguez-Sanchez IP, Martinez-Fierro ML, Paz-Michel B. A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells. Mol Med Rep 2017; 17:3503-3510. [PMID: 29286152 PMCID: PMC5802147 DOI: 10.3892/mmr.2017.8336] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Accepted: 09/07/2017] [Indexed: 12/13/2022] Open
Abstract
Osteoarthritis (OA) is a chronic disorder of synovial joints, in which there is progressive softening and disintegration of the articular cartilage. OA is the most common form of arthritis, and is the primary cause of disability and impaired quality of life in the elderly. Despite considerable medical necessity, no treatment has yet been proven to act as a disease‑modifying agent that may halt or reverse the structural progression of OA. The replacement of the joint with a prosthesis appears to be the best option in the advanced stages of the disease. A formulation (BIOF2) for cartilage regeneration has been recently developed. The present study evaluated the effects of BIOF2 on gene expression in human cell cultures, followed by efficacy trials in three OA animal models. Human synovial fluid cells that were exposed to the formulation exhibited increased transcription factor SOX‑9 (SOX9; chondrogenic factor) expression, and decreased mimecan (mineralization inducer) and macrophage‑stimulating protein receptor (osteoclastogenic factor) expression. The intra‑articular application of BIOF2 in the animal models significantly increased cartilage thickness from 12 to 31% at 28 days, compared with articular cartilage treated with saline solution. The articular area and number of chondrocytes additionally increased significantly, maintaining an unaltered chondrocyte/mm2 proportion. Evaluation of the histological architecture additionally displayed a decrease in the grade of articular damage in the groups treated with BIOF2. In conclusion, BIOF2 has proven to be effective for treating OA in animal models, most likely due to SOX9 overexpression in articular cells.
Collapse
Affiliation(s)
- Ivan Delgado-Enciso
- Cancerology State Institute, Colima State Health Services, Colima 28000, Mexico
| | - Juan Paz-Garcia
- Centro Hospitalario Union, Villa de Álvarez, Colima 28950, Mexico
| | | | | | | | | | | | - Jose L Cortes-Bazan
- Cancerology State Institute, Colima State Health Services, Colima 28000, Mexico
| | | | | | | | - Iram P Rodriguez-Sanchez
- Department of Genetics, School of Medicine, Nuevo Leon Autonomous University, Monterrey, Nuevo León 64460, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Universidad Autónoma de Zacatecas, Zacatecas 98160, México
| | | |
Collapse
|
9
|
Delgado-Enciso I, Paz-Michel B, Melnikov V, Guzman-Esquivel J, Espinoza-Gomez F, Soriano-Hernandez AD, Rodriguez-Sanchez IP, Martinez-Fierro ML, Ceja-Espiritu G, Olmedo-Buenrostro BA, Galvan-Salazar HR, Delgado-Enciso OG, Delgado-Enciso J, Lopez-Lemus UA, Montes-Galindo DA. Smoking and female sex as key risk factors associated with severe arthralgia in acute and chronic phases of Chikungunya virus infection. Exp Ther Med 2017; 15:2634-2642. [PMID: 29467856 DOI: 10.3892/etm.2017.5668] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 10/27/2017] [Indexed: 01/05/2023] Open
Abstract
Arthralgia is a potentially incapacitating condition and a persistent symptom in chronic or acute episodes of Chikungunya fever caused by infection with the Chikungunya virus (CHIKV). To the best of our knowledge, there are no reports on risk factors associated with the intensity of arthralgias in typical acute episodes of the disease. Although a number of studies have reported on risk factors associated with the development of the chronic stage of the disease, smoking habits have not been analyzed. Smoking is an interesting factor to consider since it is the main environmental risk factor for the development of rheumatoid arthritis (RA), a similar disease to CHIKV in many aspects. In the present study, 140 patients infected with CHIKV were assessed for risk factors associated with severe arthralgia intensity in the acute phase (pain of 9/10 on the visual analog scale of 0-10) and moderate to severe intensity (according to the Routine Assessment of Patient Index Data 3) 3.5 months after infection in patients that experienced the chronic phase of the disease. Women and smokers were 2- to 3-times more likely to experience severe pain in the acute and chronic stages. Likewise, the presence of severe arthralgia during the acute disease phase resulted in a 4-fold increased risk for entering the chronic phase. Smoking was a more important risk factor in males compared with females. Smoking resulted in a 20-fold increased risk for severe arthralgia during the acute phase in men, as well as a 10-fold increased risk for developing chronic disease with moderate-to-severe pain 3.5 months after the acute stage. The presence of rash, headache, muscular weakness or conjunctivitis in the acute phase, the presence of diabetes and age >40 years were considered significant risk factors due to their influence on illness progression. In conclusion, smoking and female sex were the main risk factors associated with development of severe joint pain in the acute and chronic phases of Chikungunya fever. These risk factors are similar to those associated with the development and severity of RA, possibly because the two diseases share pathophysiological mechanisms, including elevated interleukin-6 levels.
Collapse
Affiliation(s)
- Ivan Delgado-Enciso
- School of Medicine, University of Colima, Colima 28030, Mexico.,Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | | | - Valery Melnikov
- School of Medicine, University of Colima, Colima 28030, Mexico
| | - Jose Guzman-Esquivel
- Research Unit, IMSS Hospital General de Zona No. 1, Villa de Álvarez, Colima 28983, Mexico
| | | | - Alejandro D Soriano-Hernandez
- School of Medicine, University of Colima, Colima 28030, Mexico.,Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Iram P Rodriguez-Sanchez
- Department of Genetics, School of Medicine, Nuevo Leon Autonomous University, Monterrey, Nuevo Leon 64460, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico
| | - Gabriel Ceja-Espiritu
- School of Medicine, University of Colima, Colima 28030, Mexico.,Research Unit, IMSS Hospital General de Zona No. 1, Villa de Álvarez, Colima 28983, Mexico
| | | | - Hector R Galvan-Salazar
- Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico.,Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico
| | - Osiris G Delgado-Enciso
- Ethics Foundation, Study and Cancer Research of The State Institute of Cancerology of Colima, Colima 28000, Mexico
| | - Josuel Delgado-Enciso
- Ethics Foundation, Study and Cancer Research of The State Institute of Cancerology of Colima, Colima 28000, Mexico
| | - Uriel A Lopez-Lemus
- Department of Health Sciences, Biodefense and Global Infectious Diseases Center, Colima 28000, Mexico
| | | |
Collapse
|
10
|
Madrigal-Perez VM, García-Rivera A, Rodriguez-Hernandez A, Ceja-Espiritu G, Briseño-Gomez XG, Galvan-Salazar HR, Soriano-Hernandez AD, Guzman-Esquivel J, Martinez-Fierro ML, Newton-Sanchez OA, Buenrostro BAO, Rodriguez-Sanchez IP, López-Lemus UA, Lara-Esqueda A, Delgado-Enciso I. Preclinical analysis of nonsteroidal anti-inflammatory drug usefulness for the simultaneous prevention of steatohepatitis, atherosclerosis and hyperlipidemia. Int J Clin Exp Med 2015; 8:22477-22483. [PMID: 26885230 PMCID: PMC4730016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 11/21/2015] [Indexed: 06/05/2023]
Abstract
Nonalcoholic steatohepatitis (NASH) is currently one of the primary liver diseases. Recent studies have shown a clinical relation between NASH and atherosclerosis. There is much interest in these two diseases because they are both associated with great morbidity and mortality. Inflammation and the overexpression of COX-2 participate in the pathophysiology of the two diseases, and therefore simultaneous treatment is feasible. The role of the four NSAIDs, meclofenamate, mefenamate, flufenamate, and aspirin, was analyzed in a mouse model of NASH, as well as preclinical atherosclerosis induced by a high-fat diet (HFD). Six mouse groups were formed. Five of the groups were fed a high-fat diet for 6 months and one group was fed a standard diet, acting as the normality reference. Of the five groups fed a high-fat diet, four received a NSAID, each of them identified by the specific drug administered. One group received no treatment. Serum markers (cholesterol, triglycerides, ALT, and AST) and histologic changes in the aorta and liver were analyzed for the study. Aspirin significantly reduced the hepaticsteatosis. All the drugs significantly reduced the hepatic inflammatory infiltrate. In relation to atherosclerosis, there were significant reductions in all the study variables with the use of aspirin and flufenamate. The four medications were able to stop steatosis from progressing into steatohepatitis by reducing inflammation. However, aspirin was the most beneficial, simultaneously reducing steatosis, atherosclerosis, and serum cholesterol levels.
Collapse
Affiliation(s)
- Violeta M Madrigal-Perez
- School of Medicine, University of Colima Av. Universidad 333, Col. Las Víboras. Colima 28030, Mexico
| | - Alejandro García-Rivera
- School of Medicine, University of Colima Av. Universidad 333, Col. Las Víboras. Colima 28030, Mexico
| | | | - Gabriel Ceja-Espiritu
- School of Medicine, University of Colima Av. Universidad 333, Col. Las Víboras. Colima 28030, Mexico
| | - Xochitl G Briseño-Gomez
- Cancerology State Institute, Colima State Health Services Av. Liceo de Varones 401. Col. La Esperanza, Colima 28000, México
| | - Hector R Galvan-Salazar
- School of Medicine, University of ColimaAv. Universidad 333, Col. Las Víboras. Colima 28030, Mexico; Cancerology State Institute, Colima State Health ServicesAv. Liceo de Varones 401. Col. La Esperanza, Colima 28000, México
| | - Alejandro D Soriano-Hernandez
- School of Medicine, University of ColimaAv. Universidad 333, Col. Las Víboras. Colima 28030, Mexico; Cancerology State Institute, Colima State Health ServicesAv. Liceo de Varones 401. Col. La Esperanza, Colima 28000, México
| | - Jose Guzman-Esquivel
- Hospital General de Zona No1. IMSS Av. De los Maestros 149. Col. Centro. Colima 28000, México
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Universidad Autónoma de Zacatecas Km 6 Carr. Zacatecas-Guadalajara s/n. Ejido La Escondida, Zacatecas 98160, Mexico
| | - Oscar A Newton-Sanchez
- School of Medicine, University of Colima Av. Universidad 333, Col. Las Víboras. Colima 28030, Mexico
| | | | - Iram P Rodriguez-Sanchez
- Department of Genetics, School of Medicine, Nuevo Leon Autonomous University Ave. Madero s/n con Dr. Eduardo Aguirre Pequeño. Col. Mitras Centro, Monterrey, Nuevo León 64460, México
| | - Uriel A López-Lemus
- School of Medicine, University of Colima Av. Universidad 333, Col. Las Víboras. Colima 28030, Mexico
| | - Agustin Lara-Esqueda
- Cancerology State Institute, Colima State Health Services Av. Liceo de Varones 401. Col. La Esperanza, Colima 28000, México
| | - Ivan Delgado-Enciso
- School of Medicine, University of ColimaAv. Universidad 333, Col. Las Víboras. Colima 28030, Mexico; Cancerology State Institute, Colima State Health ServicesAv. Liceo de Varones 401. Col. La Esperanza, Colima 28000, México
| |
Collapse
|
11
|
Soriano-Hernandez AD, Madrigal-Pérez D, Galvan-Salazar HR, Martinez-Fierro ML, Valdez-Velazquez LL, Espinoza-Gómez F, Vazquez-Vuelvas OF, Olmedo-Buenrostro BA, Guzman-Esquivel J, Rodriguez-Sanchez IP, Lara-Esqueda A, Montes-Galindo DA, Delgado-Enciso I. Anti-inflammatory drugs and uterine cervical cancer cells: Antineoplastic effect of meclofenamic acid. Oncol Lett 2015; 10:2574-2578. [PMID: 26622892 DOI: 10.3892/ol.2015.3580] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 05/22/2015] [Indexed: 01/26/2023] Open
Abstract
Uterine cervical cancer (UCC) is one of the main causes of cancer-associated mortality in women. Inflammation has been identified as an important component of this neoplasia; in this context, anti-inflammatory drugs represent possible prophylactic and/or therapeutic alternatives that require further investigation. Anti-inflammatory drugs are common and each one may exhibit a different antineoplastic effect. As a result, the present study investigated different anti-inflammatory models of UCC in vitro and in vivo. Celecoxib, sulindac, nimesulide, dexamethasone, meclofenamic acid, flufenamic acid and mefenamic acid were tested in UCC HeLa, VIPA, INBL and SiHa cell lines. The cytotoxicity of the drugs was evaluated in vitro. Celecoxib, sulindac, nimesulide, mefenamic acid and flufenamic acid presented with slight to moderate toxicity (10-40% of cell death corresponding to 100 µM) in certain cell lines, while meclofenamic acid exhibited significant cytotoxicity in all essayed cell lines (50-90% of cell death corresponding to 100 µM). The meclofenamic acid was tested in murine models (immunodeficient and immunocompetent) of UCC, which manifested a significant reduction in tumor growth and increased mouse survival. It was demonstrated that of the evaluated anti-inflammatory drugs, meclofenamic acid was the most cytotoxic, with a significant antitumor effect in murine models. Subsequent studies are necessary to evaluate the clinical utility of this drug.
Collapse
Affiliation(s)
- Alejandro D Soriano-Hernandez
- School of Medicine, University of Colima, Colima, Colima 28030, Mexico ; Cancerology State Institute, Colima State Health Services, Colima, Colima 28000, Mexico
| | | | - Hector R Galvan-Salazar
- School of Medicine, University of Colima, Colima, Colima 28030, Mexico ; Cancerology State Institute, Colima State Health Services, Colima, Colima 28000, Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autononous University of Zacatecas, Zacatecas, Zacatecas 98160, Mexico
| | | | | | | | | | - Jose Guzman-Esquivel
- General Hospital of Zone No. 1, Mexican Institute of Social Security, Colima, Colima 28000, Mexico
| | - Iram P Rodriguez-Sanchez
- Department of Genetics, School of Medicine, Nuevo Leon Autonomous University, Monterrey, Nuevo León 64460, Mexico
| | - Agustin Lara-Esqueda
- Cancerology State Institute, Colima State Health Services, Colima, Colima 28000, Mexico
| | - Daniel A Montes-Galindo
- School of Medicine, University of Colima, Colima, Colima 28030, Mexico ; School of Chemistry, University of Colima, Coquimatlán, Colima 28400, Mexico
| | - Ivan Delgado-Enciso
- School of Medicine, University of Colima, Colima, Colima 28030, Mexico ; Cancerology State Institute, Colima State Health Services, Colima, Colima 28000, Mexico
| |
Collapse
|
12
|
Soriano-Hernandez AD, Madrigal-Perez DG, Galvan-Salazar HR, Arreola-Cruz A, Briseño-Gomez L, Guzmán-Esquivel J, Dobrovinskaya O, Lara-Esqueda A, Rodríguez-Sanchez IP, Baltazar-Rodriguez LM, Espinoza-Gomez F, Martinez-Fierro ML, de-Leon-Zaragoza L, Olmedo-Buenrostro BA, Delgado-Enciso I. The protective effect of peanut, walnut, and almond consumption on the development of breast cancer. Gynecol Obstet Invest 2015; 80:89-92. [PMID: 26183374 DOI: 10.1159/000369997] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 11/18/2014] [Indexed: 12/21/2022]
Abstract
BACKGROUND/AIMS Breast cancer is the most common gynecologic malignancy known worldwide. The consumption of certain foods may modify the risk for its development. Peanuts and other seeds have shown anticarcinogenic effects in vitro, but there are a few studies that evaluate the effect of their consumption on the development of breast cancer. The aim of the present study was to determine whether there is an association between the consumption of peanuts, walnuts, and almonds and the development of breast cancer. METHODS We analyzed 97 patients presenting with breast cancer and 104 control subjects that did not have the pathology (BIRADS 1-2). An analysis of the main clinical characteristics and lifelong seed consumption was carried out. The association between the consumption of these foods and the risk for breast cancer was estimated by odds ratios and 95% confidence intervals, controlling other risk factors, using the Mantel-Haenszel analysis. RESULTS The high consumption of peanuts, walnuts, or almonds significantly reduced the risk for breast cancer by 2-3 times. This protective effect was not found with low or moderate seed consumption when compared with null consumption. CONCLUSIONS High consumption of peanuts, walnuts, and almonds appears to be a protective factor for the development of breast cancer.
Collapse
|
13
|
Soriano-Hernández AD, Galvan-Salazar HR, Montes-Galindo DA, Rodriguez-Hernandez A, Martinez-Martinez R, Guzman-Esquivel J, Valdez-Velazquez LL, Baltazar-Rodriguez LM, Espinoza-Gómez F, Rojas-Martinez A, Ortiz-Lopez R, Gonzalez-Alvarez R, Delgado-Enciso I. Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. Int Urol Nephrol 2011; 44:471-7. [DOI: 10.1007/s11255-011-0012-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2011] [Accepted: 05/24/2011] [Indexed: 01/11/2023]
|